Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Ovarian Neoplasms 29Neoplasms 14Breast Neoplasms 8Fallopian Tube Neoplasms 7Prostatic Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 2Prostatic Neoplasms, Castration-Resistant 2Melanoma 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Recurrence 1Prostatic Diseases 1Pancreatic Neoplasms 1Ovarian Diseases 1Osteosarcoma 1Neuroblastoma 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma 1Lung Neoplasms 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hereditary Sensory and Autonomic Neuropathies 1

Interventions

Pemetrexed 3mifamurtide 2lenvatinib 2dostarlimab 2belinostat 2Ifosfamide 2Granulocyte-Macrophage Colony-Stimulating Factor 2Gemcitabine 2Etoposide 2Drug Therapy 2Cyclophosphamide 2Cisplatin 2vactosertib 1surufatinib 1sintilimab 1robatumumab 1ridaforolimus 1reolysin 1pembrolizumab 1pazopanib 1omburtamab I-131 1niraparib 1isophosphamide mustard 1fludarabine 1endostar protein 1dinutuximab 1copanlisib 1cc-486 1cabozantinib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Osteosarcoma × niraparib × Clear all
NCT04544995 2026-01-21

Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)

GlaxoSmithKline

Phase 1 Terminated
47 enrolled 43 charts
CNSSarcoma

Neoplasms, Neuroblastoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡